.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
AstraZeneca
Merck
Novartis
Moodys
Johnson and Johnson
Mallinckrodt
Daiichi Sankyo
Queensland Health

Generated: December 16, 2017

DrugPatentWatch Database Preview

Jazz Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JAZZ PHARMS, and when can generic versions of JAZZ PHARMS drugs launch?

JAZZ PHARMS has five approved drugs.

There are twenty-six US patents protecting JAZZ PHARMS drugs.

There are ninety-eight patent family members on JAZZ PHARMS drugs in thirty countries and thirty-one supplementary protection certificates in seven countries.

Summary for Jazz Pharms

International Patents:98
US Patents:26
Tradenames:5
Ingredients:5
NDAs:5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jazz PharmsXYREMsodium oxybateSOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► Subscribe► Subscribe
Jazz PharmsXYREMsodium oxybateSOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► Subscribe► Subscribe
Jazz PharmsXYREMsodium oxybateSOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► Subscribe► Subscribe
Jazz Pharms IntlPRIALTziconotide acetateINJECTABLE;INTRATHECAL021060-003Dec 28, 2004DISCNNoNo► Subscribe► Subscribe► Subscribe
Jazz PharmsXYREMsodium oxybateSOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-005Jul 9, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Jazz PharmsXYREMsodium oxybateSOLUTION;ORAL021196-001Jul 17, 2002AARXYesYes► Subscribe► SubscribeY► Subscribe
Jazz Pharms IntlPRIALTziconotide acetateINJECTABLE;INTRATHECAL021060-001Dec 28, 2004RXYesYes► Subscribe► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
Jazz PharmsLUVOX CRfluvoxamine maleateCAPSULE, EXTENDED RELEASE;ORAL022033-002Feb 28, 2008DISCNYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Jazz Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-002Feb 10, 2004► Subscribe► Subscribe
Jazz Pharms IntlPRIALTziconotide acetateINJECTABLE;INTRATHECAL021060-001Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-001Feb 10, 2004► Subscribe► Subscribe
Jazz Pharms IntlPRIALTziconotide acetateINJECTABLE;INTRATHECAL021060-004Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms IntlPRIALTziconotide acetateINJECTABLE;INTRATHECAL021060-002Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007► Subscribe► Subscribe
Jazz Pharms IntlPRIALTziconotide acetateINJECTABLE;INTRATHECAL021060-004Dec 28, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-005Jul 9, 2010► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-001Feb 10, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-006Jul 9, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JAZZ PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
sodium oxybateOral Solution500 mg/mLXYREM7/8/2010
fluvoxamine maleateExtended-release Capsules100 mgLUVOX CR4/20/2009
fluvoxamine maleateExtended-release150 mgLUVOX CR4/13/2009

Non-Orange Book Patents for Jazz Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,472,431 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy► Subscribe
5,587,454 Omega conopeptide compositions► Subscribe
7,268,109Method for reducing pain► Subscribe
7,833,973Pharmaceutical formulations for reducing pain► Subscribe
8,461,203Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy► Subscribe
8,268,774Method for reducing pain► Subscribe
7,524,812Pharmaceutical formulation comprising ziconotide► Subscribe
6,136,786 Method for enhancing analgesia► Subscribe
5,994,305 Method of treating inflammation► Subscribe
8,513,198Pharmaceutical formulation for reducing pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Jazz Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office0625162► Subscribe
Israel143733► Subscribe
Spain2167921► Subscribe
Germany69225499► Subscribe
Australia8865998► Subscribe
Hong Kong1013832► Subscribe
Portugal1003484► Subscribe
Singapore11201505029Q► Subscribe
Spain2525720► Subscribe
Hungary229152► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Jazz Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
90064-1Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Colorcon
Fish and Richardson
Federal Trade Commission
McKinsey
Harvard Business School
US Army
Cipla
QuintilesIMS
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot